Quantinno Capital Management LP Raises Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Quantinno Capital Management LP lifted its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 43.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,145 shares of the medical device company’s stock after purchasing an additional 9,385 shares during the quarter. Quantinno Capital Management LP’s holdings in Tandem Diabetes Care were worth $1,321,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Diversified Trust Co raised its holdings in Tandem Diabetes Care by 11.1% during the second quarter. Diversified Trust Co now owns 14,635 shares of the medical device company’s stock worth $590,000 after purchasing an additional 1,462 shares in the last quarter. ORG Partners LLC acquired a new position in Tandem Diabetes Care in the second quarter worth about $31,000. Assenagon Asset Management S.A. increased its holdings in shares of Tandem Diabetes Care by 37.5% during the second quarter. Assenagon Asset Management S.A. now owns 311,427 shares of the medical device company’s stock worth $12,547,000 after buying an additional 85,000 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Tandem Diabetes Care by 33.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,936 shares of the medical device company’s stock valued at $239,000 after purchasing an additional 1,486 shares in the last quarter. Finally, MN Wealth Advisors LLC boosted its position in shares of Tandem Diabetes Care by 3.1% during the second quarter. MN Wealth Advisors LLC now owns 14,723 shares of the medical device company’s stock worth $593,000 after purchasing an additional 440 shares in the last quarter.

Tandem Diabetes Care Stock Down 0.6 %

NASDAQ TNDM opened at $34.31 on Friday. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -17.78 and a beta of 1.33. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 1-year low of $21.85 and a 1-year high of $53.69. The stock’s 50 day moving average is $33.00 and its two-hundred day moving average is $39.82.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. The firm had revenue of $243.97 million during the quarter, compared to analyst estimates of $224.14 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company’s revenue for the quarter was up 31.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.38) EPS. Equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Kim D. Blickenstaff sold 10,000 shares of Tandem Diabetes Care stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the director now owns 195,190 shares in the company, valued at $5,855,700. This trade represents a 4.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Citigroup lowered their price target on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday. The Goldman Sachs Group initiated coverage on shares of Tandem Diabetes Care in a research report on Friday, October 4th. They set a “neutral” rating and a $46.00 price objective for the company. Sanford C. Bernstein initiated coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They set an “outperform” rating and a $42.00 price objective on the stock. Morgan Stanley raised Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price for the company in a report on Monday, December 2nd. Finally, Robert W. Baird lowered their price objective on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research report on Thursday, November 7th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and a consensus price target of $53.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.